Show an ad over header. AMP

I am the FIRST

The wide range of coronavirus symptoms is making it difficult to stop the disease

The wide-ranging symptoms and many manifestations of COVID-19 are complicating efforts to treat the disease and stop its spread.

The big picture: There are very few diseases that everyone experiences the same. But the patterns of disease with COVID-19 are unusual compared to other recent pandemics, and it could usher in a new framework for thinking about disease.

The range of experiences in people infected with SARS-CoV-2, the virus that causes COVID-19, spans from no symptoms to hospitalization to death, an observation NIAID director Anthony Fauci and other experts have repeatedly made recently.

  • "In SARS-Cov-2 , there is an extreme divergence in host responses. We don’t yet know what is leading to that," says immunologist José Ordovas-Montañes of Boston Children's Hospital.

Details: Many people have mild symptoms of the disease — or none at all, meaning they can be unknowingly carrying and spreading the virus and complicating efforts to control its spread.

  • 40%–45% of people infected with SARS-CoV-2 don't develop symptoms, according to one estimate based on several case studies.
  • By comparison, 13% of health care workers infected with SARS-CoV-1, the virus behind the 2003 epidemic, were asymptomatic in one study in Singapore.
  • But for many respiratory viruses, the rate of infection without symptoms is more than 70%.

On the other end of the spectrum are the roughly 1 in 5 people who are infected and need to be hospitalized.

  • Beyond pneumonia and acute respiratory distress syndrome, the long and varied list of common manifestations of COVID-19 in hospitalized patients includes cardiac, neurological, renal, hepatic, gastrointestinal, endocrine, thrombotic, and dermatological complications, according to a recent review by Aakriti Gupta of the Columbia University Irving Medical Center.
  • "This virus is proving to be more than just a respiratory virus in terms of the manifestations, which we've seen with other respiratory viruses," says Amesh Adalja, a senior scholar at the John Hopkins Center for Health Security.
  • Other viruses, like influenza, SARS-CoV-1 and Ebola, can affect the body in multiple ways.
  • But with COVID-19, "the proportion of people in which this multiple organ injury is occurring is higher than anything we’ve seen before," says Gupta. For example, 40%–50% of hospitalized COVID-19 patients and up to 80% of patients admitted to the ICU have acute kidney injury, usually in addition to lung injury, compared to about 7% of patients with SARS.

The intrigue: It's possible other pandemic viruses — like the 1918 flu — had a wide range of different outcomes, but the molecular tools and diagnostics didn't exist to spot them. Or in the case of the coronaviruses that cause the common cold and don't kill people, we don't pay attention to those differences or bother to look for them.

  • But COVID-19 does kill and, as data and science rapidly amass about the virus, the differences are more explicit — and more concerning.
  • "Each virus has this particular balance of the types of cases you are going to get," says Ordovas-Montañes. "This virus has particularly captivated our attention because of how balanced it is across that spectrum."

What's happening: Researchers are trying to tease out the factors behind COVID-19's range.

There is the virus itself. "Coronaviruses are unusual in that they attack both the respiratory and gastrointestinal systems," says Rachel Roper, a virologist at East Carolina University.

  • SARS-CoV-2 targets the ACE2 receptor on host cells to infect them. That receptor is expressed in many of the body’s tissues, and some studies find particles of the virus in heart, kidney and gut cells, suggesting it can get to other organs and possibly damage them directly.
  • Or it could be that the virus is impairing the body’s innate immune responses, affecting pathways that regulate key processes in the body, or causing inflammation — any of which may allow the virus to reach into unexpected organ systems.

There is the person it infects, with their genetics, behaviors and environment. A host of pre-existing conditions — for example, previous lung and heart disease — increases the risk of serious COVID-19 complications.

And there is the society that person lives in. Geographic and racial disparities in this pandemic suggest other factors, like the distribution of health services, may need to be considered, says C. Brandon Ogbunu, an assistant professor at Yale University who studies disease evolution and ecology.

  • "Even more so than other outbreaks, the variation from person to person, the multisystem nature, the way it hits demographics different, the way the disease manifests differently in national contexts — it defies a simple medical or biomedical narrative," he says.
  • COVID-19 may be more akin to noninfectious diseases — like diabetes and schizophrenia — that have complex interactions with sociological, historical and behavioral factors," says Ogbunu.

The bottom line: "The story of understanding COVID-19 has been the story of understanding these diversities," says Ogbunu. "This is a test of our modern understanding of what a disease is."

4 ffp

Why the startup world needs to ditch "unicorns" for "dragons"

When Aileen Lee originally coined the term "unicorn" in late 2013, she was describing the 39 "U.S.-based software companies started since 2003 and valued at over $1 billion by public or private market investors."

Flashback: It got redefined in early 2015 by yours truly and Erin Griffith, in a cover story for Fortune, as any privately-held startup valued at $1 billion or more. At the time, we counted 80 of them.

Keep reading... Show less

Scoop: Facebook's new moves to lower News Feed's political volume

Facebook plans to announce that it will de-emphasize political posts and current events content in the News Feed based on negative user feedback, Axios has learned. It also plans to expand tests to limit the amount of political content that people see in their News Feeds to more countries outside of the U.S.

Why it matters: The changes could reduce traffic to some news publishers, particularly companies that post a lot of political content.

Keep reading... Show less

Scoop: Amazon quietly getting into live audio business

Amazon is investing heavily in a new live audio feature that's similar to other live audio offerings like Clubhouse, Twitter Spaces and Spotify's new live audio platform, sources tell Axios.

Why it matters: As with Amazon's efforts in podcasting and music subscriptions, the company sees live audio as a way to bolster the types of content it can offer through its voice assistant, Alexa, and its smart speaker products.

Keep reading... Show less

Hurricane Ida exposes America's precarious energy infrastructure

The powerful hurricane that plunged New Orleans into darkness for what could be weeks is the latest sign that U.S. power systems are not ready for a warmer, more volatile world.

The big picture: “Our current infrastructure is not adequate when it comes to these kinds of weather extremes,” Joshua Rhodes, a University of Texas energy expert, tells Axios.

Keep reading... Show less

"We must go further": 70% of adults in European Union are fully vaccinated

About 70% of adults in the European Union are fully vaccinated against COVID-19, Ursula von der Leyen, the president of the European Commission, said Tuesday.

Why it matters: The milestone makes the E.U. one of the world's leaders in inoculations, after an initially lagging vaccine campaign, the New York Times notes.

Keep reading... Show less

What Elizabeth Holmes jurors will be asked ahead of fraud trial

Jury selection begins today in USA v. Elizabeth Holmes, with the actual jury trial to get underway on Sept. 8.

Why it matters: Theranos was the biggest fraud in Silicon Valley history, putting both hundreds of millions of dollars and thousands of patients' health at risk.

Keep reading... Show less



Get Goodhumans in your inbox

Most Read

More Stories